Quantcast

Latest Hoffmann-La Roche Inc. Stories

2010-03-02 06:00:00

MADISON, Wis., March 2 /PRNewswire/ -- Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11. The workshop, entitled "Toxicology in the 21st Century: Stem Cells in Drug Discovery and Development," will present the current understanding of pluripotent stem cells and their utility in providing cellular models, how they are being employed to...

2009-06-09 07:00:00

- SYNCHRONY Study Published in The Lancet Supports Cardio-Protective Potential of Aleglitazar - NUTLEY, N.J., June 9 /PRNewswire/ -- Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at...

2009-05-28 07:00:00

NUTLEY, N.J., May 28 /PRNewswire/ -- Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored as the 2009 recipient of the Lifetime Achievement Award presented by the North Jersey Section of the American Chemical Society (ACS) on May 27, 2009 at Fairleigh Dickenson University (http://theindicator.org/2009-05.pdf). The chemist has a world-wide reputation as a leader and innovator in the field of peptide chemistry and the application of peptide chemistry to drug discovery....

2009-05-01 07:00:00

NUTLEY, N.J., May 1 /PRNewswire/ -- Three Roche employees were recognized for their significant contributions to industry in New Jersey at the 2009 TWIN Awards Dinner held April 30, 2009. Honored were Nancy Shore DiLella, J.D., senior counsel and managing attorney; Theresa Martinez, marketing director for the leading hepatitis C treatment, Pegasys(R) (peginterferon alfa-2a); and Linda Lee-Mathieson, Director, Clinical Management, Pharma Development Operations. "These individuals are...

2009-04-24 18:35:00

Start of trial triggers $10 million milestone payment to Pharmasset PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate the dose and duration of treatment of R7128 in combination with Roche's...

2009-04-23 07:00:00

- State-of-the-art facility designed to foster drug delivery - MADISON, Wis. and NUTLEY, N.J., April 23 /PRNewswire/ -- Today, Roche Madison Inc. officially opened the doors to a new state-of-the-art facility with chemistry and biology labs at the University of Wisconsin Research Park in Madison. Part of the global RNA Therapeutics group within Roche, the group's research focuses on the discovery and development of innovative...

2009-01-14 16:00:00

- Largest Prospective Study Demonstrates Treatment Success, and Highlights Potential Factors that Affect Health Outcomes, in Latino Population Suffering from Chronic Hepatitis C - NUTLEY, N.J., Jan. 14 /PRNewswire/ -- Results from the LATINO study, the largest study conducted to-date in Latino patients with the hepatitis C virus (HCV), were published today in The New England Journal of Medicine (NEJM).(1) This Roche study demonstrated that HCV can be successfully treated among Latino...

2009-01-13 17:00:00

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer. In the study, patients receiving XELOX...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related